{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:18:01Z","timestamp":1793762281418,"version":"4.6.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Groupement de coop\u00e9ration sanitaire"},{"name":"F\u00e9d\u00e9ration Hospitalo-Universitaire"},{"name":"CARNAVAL"},{"DOI":"10.13039\/100019899","name":"AVIESAN","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019899","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Therapeutic advancements have significantly enhanced cancer patient survival rates yet concomitantly increased the prevalence of associated toxicities, such as cancer therapy-related cardiac dysfunction (CTRCD), either symptomatic (heart failure) or not. Using the World Health Organization's VigiBase\u00ae individual case safety report database, the aim was to establish the association between anticancer drugs and CTRCD reporting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>This study was a disproportionality analysis conducted in VigiBase\u00ae from the initial report of any anticancer drug until 29 February 2024. Reporting odds ratios for CTRCD were evaluated using a stepwise selection procedure and multivariable-adjusted analyses. Subsequently, secondary analyses consisted of the description of CTRCD cases associated with the identified anticancer drugs. ClinicalTrials.gov registration number: NCT06268535. Among 36 580 288 database reports, 42 828 CTRCD cases associated with at least one anticancer drug were identified with death reported in 20.6% of cases (8833 CTRCD cases). Primary analysis revealed 25 anticancer drugs significantly associated with CTRCD reporting, with trastuzumab, doxorubicin, and bortezomib exhibiting the strongest associations. Cancer therapy-related cardiac dysfunction reporting was associated with kinase inhibitors, including BCR-ABL inhibitors, ibrutinib, and osimertinib. New signals were identified for trabectedin, clofarabine, fludarabine, entrectinib, gemtuzumab ozogamicin, and anagrelide. In contrast, immune checkpoint inhibitors and most anti-vascular endothelial growth factor therapies showed no association with CTRCD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This disproportionality study identified 25 anticancer drugs significantly associated with CTRCD reporting, including new signals. It highlights discrepancies compared with drugs recommended for cardiac dysfunction evaluation in the 2022 ESC Guidelines. This underscores the importance of including CTRCD as a safety endpoint in cancer studies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaf027","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T05:31:13Z","timestamp":1744867873000},"page":"459-468","source":"Crossref","is-referenced-by-count":7,"title":["Identification of anticancer drugs associated to cancer therapy-related cardiac dysfunction: a VigiBase\u00ae disproportionality analysis"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2297-4418","authenticated-orcid":false,"given":"Damien","family":"Legallois","sequence":"first","affiliation":[{"name":"Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE , Avenue de la C\u00f4te de Nacre, F-14000 Caen ,","place":["France"]},{"name":"Department of Cardiology, Caen-Normandy University Hospital, PICARO Cardio-Oncology Program , Avenue de la C\u00f4te de Nacre, F-14000 Caen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lique","family":"Da Silva","sequence":"additional","affiliation":[{"name":"Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE , Avenue de la C\u00f4te de Nacre, F-14000 Caen ,","place":["France"]},{"name":"Department of Pharmacology, Caen-Normandy University Hospital, PICARO Cardio-Oncology Program , Avenue de la C\u00f4te de Nacre, F-14000 Caen ,","place":["France"]},{"name":"Department of Medical Oncology, Caen-Normandy University Hospital, PICARO Cardio-Oncology Program , Avenue de la C\u00f4te de Nacre, F-14000 Caen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Alexandre","sequence":"additional","affiliation":[{"name":"Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE , Avenue de la C\u00f4te de Nacre, F-14000 Caen ,","place":["France"]},{"name":"Department of Pharmacology, Caen-Normandy University Hospital, PICARO Cardio-Oncology Program , Avenue de la C\u00f4te de Nacre, F-14000 Caen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Milliez","sequence":"additional","affiliation":[{"name":"Normandie Univ, UNICAEN, INSERM U1237 PhIND, GIP Cyceron, Boulevard Henri Becquerel , F-14000 Caen ,","place":["France"]},{"name":"Department of Cardiology, Caen-Normandy University Hospital , Avenue de la C\u00f4te de Nacre, F-14000 Caen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Sabatier","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Caen-Normandy University Hospital , Avenue de la C\u00f4te de Nacre, F-14000 Caen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien","family":"Blanchart","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Caen-Normandy University Hospital , Avenue de la C\u00f4te de Nacre, F-14000 Caen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Flore","family":"Plane","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Caen-Normandy University Hospital, PICARO Cardio-Oncology Program , Avenue de la C\u00f4te de Nacre, F-14000 Caen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3103-9739","authenticated-orcid":false,"given":"Jonaz","family":"Font","sequence":"additional","affiliation":[{"name":"Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE , Avenue de la C\u00f4te de Nacre, F-14000 Caen ,","place":["France"]},{"name":"Department of Cardiology, Caen-Normandy University Hospital , Avenue de la C\u00f4te de Nacre, F-14000 Caen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basile","family":"Chr\u00e9tien","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine, Nagoya University Hospital , 65 Tsurumai-cho, Showa-ku, Nagoya 466-8560 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0449-6261","authenticated-orcid":false,"given":"Charles","family":"Dolladille","sequence":"additional","affiliation":[{"name":"Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE , Avenue de la C\u00f4te de Nacre, F-14000 Caen ,","place":["France"]},{"name":"Department of Pharmacology, Caen-Normandy University Hospital, PICARO Cardio-Oncology Program , Avenue de la C\u00f4te de Nacre, F-14000 Caen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"2025081219534132000_pvaf027-B1","first-page":"865","article-title":"Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Clinical Consensus Statement of the Acute CardioVascular Care Association (ACVC) and the ESC council of Cardio-Oncology-part 2: acute heart failure, acute myocardial diseases, acute venous thromboembolic diseases, and acute arrhythmias","volume":"11","author":"Gevaert","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2025081219534132000_pvaf027-B2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2021","journal-title":"Eur Heart J"},{"key":"2025081219534132000_pvaf027-B3","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaccao.2021.06.003","article-title":"Cardiovascular manifestations from therapeutic radiation","volume":"3","author":"Mitchell","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2025081219534132000_pvaf027-B4","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2025081219534132000_pvaf027-B5","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jacc.2019.11.059","article-title":"Reporting of cardiovascular events in clinical trials supporting FDA approval of contemporary cancer therapies","volume":"75","author":"Bonsu","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025081219534132000_pvaf027-B6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"2025081219534132000_pvaf027-B7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.therap.2017.08.006","article-title":"Case-non-case studies: principle, methods, bias and interpretation","volume":"73","author":"Faillie","year":"2018","journal-title":"Therapie"},{"key":"2025081219534132000_pvaf027-B8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2165\/00002018-200730070-00009","article-title":"Standardised MedDRA queries","volume":"30","author":"Mozzicato","year":"2007","journal-title":"Drug Saf"},{"key":"2025081219534132000_pvaf027-B9","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2025081219534132000_pvaf027-B10","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1534\/genetics.103.021683","article-title":"Modifying the Schwarz Bayesian information criterion to locate multiple interacting quantitative trait loci","volume":"167","author":"Bogdan","year":"2004","journal-title":"Genetics"},{"key":"2025081219534132000_pvaf027-B11","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/ejhf.2984","article-title":"Patient mortality following new-onset heart failure stratified by cancer type and status","volume":"25","author":"Nouhravesh","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2025081219534132000_pvaf027-B12","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","article-title":"Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry","volume":"41","author":"L\u00f3pez-Send\u00f3n","year":"2020","journal-title":"Eur Heart J"},{"key":"2025081219534132000_pvaf027-B13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II\u20142024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"key":"2025081219534132000_pvaf027-B14","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/11594540-000000000-00000","article-title":"Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care","volume":"34","author":"Mart\u00edn-Merino","year":"2011","journal-title":"Drug Saf"},{"key":"2025081219534132000_pvaf027-B15","doi-asserted-by":"crossref","first-page":"e000082","DOI":"10.1161\/HCG.0000000000000082","article-title":"Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American heart association","volume":"14","author":"Okwuosa","year":"2021","journal-title":"Circ Genom Precis Med"},{"key":"2025081219534132000_pvaf027-B16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.acvd.2019.09.006","article-title":"Heart failure and atrial tachyarrhythmia on Abiraterone: a pharmacovigilance study","volume":"113","author":"Bretagne","year":"2020","journal-title":"Arch Cardiovasc Dis"},{"key":"2025081219534132000_pvaf027-B17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","article-title":"Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer","volume":"133","author":"Bhatia","year":"2016","journal-title":"Circulation"},{"key":"2025081219534132000_pvaf027-B18","first-page":"100332","article-title":"Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"2025081219534132000_pvaf027-B19"},{"key":"2025081219534132000_pvaf027-B20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cardfail.2024.08.045","article-title":"Cardio-oncology and heart failure: a scientific statement from the Heart Failure Society of America","volume":"31","author":"Bloom","year":"2024","journal-title":"J Card Fail"},{"key":"2025081219534132000_pvaf027-B21","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.leukres.2015.03.014","article-title":"Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study","volume":"39","author":"Tortorella","year":"2015","journal-title":"Leuk Res"},{"key":"2025081219534132000_pvaf027-B22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","article-title":"Cardiovascular toxicity of proteasome inhibitors: underlying mechanisms and management strategies: JACC: CardioOncology state-of-the-art review","volume":"5","author":"Georgiopoulos","year":"2023","journal-title":"JACC CardioOncol"},{"key":"2025081219534132000_pvaf027-B23","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025081219534132000_pvaf027-B24","doi-asserted-by":"crossref","first-page":"e200423","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025081219534132000_pvaf027-B25","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025081219534132000_pvaf027-B26","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis","volume":"42","author":"Dolladille","year":"2021","journal-title":"Eur Heart J"},{"key":"2025081219534132000_pvaf027-B27","doi-asserted-by":"crossref","first-page":"102536","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2025081219534132000_pvaf027-B28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","article-title":"Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis","volume":"53","author":"Abdel-Qadir","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2025081219534132000_pvaf027-B29","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"McKay","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2025081219534132000_pvaf027-B30","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdv147","article-title":"Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma","volume":"26","author":"Izzedine","year":"2015","journal-title":"Ann Oncol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaf027\/62998528\/pvaf027.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/5\/459\/62998528\/pvaf027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/5\/459\/62998528\/pvaf027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T23:53:50Z","timestamp":1755042830000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/11\/5\/459\/8119084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,4,24]]},"published-print":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf027","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,4,24]]}}}